Wednesday, March 17, 2021 8:18:36 AM
7:29 am ET March 17, 2021 (Dow Jones) Print
By Chris Wack
Immatics NV said it saw positive clinical data from the dose escalation cohorts of its ongoing Phase 1 trials for its engineered Adoptive Cell Therapy approach.
The biopharmaceutical company said the treatment of patients with ACTengine product candidates IMA201, IMA202 and IMA203 at initial dose levels below one billion transduced cells intended to establish safety and first biological activity, showed first anti-tumor activity with 9 out of 10 evaluable patients showing disease control as well as tumor shrinkage observed in 8 out of 10 patients including one partial response.
Immatics said clinical observations were consistent with observed robust engraftment, persistence and tumor infiltration of infused ACTengine T cells. Overall, all product candidates demonstrated a manageable safety and tolerability profile.
The primary objectives of the Phase 1 studies are to study the safety profile of the ACTengine product candidates in patients with target-positive solid cancers and to determine the recommended Phase 2 dose. Secondary objectives include the assessment of T cell engraftment, persistence and infiltration into the tumor, and the assessment of objective tumor responses.
ACTengine product candidates were well tolerated. All adverse events were transient and manageable. No dose-limiting toxicities were observed in patients treated with IMA201 and IMA202. One patient receiving IMA203 at dose level 2 experienced a dose limiting toxicity as defined in the trial protocol. The reaction was transient and fully resolved within 48 hours after onset.
Immatics shares were up 12%, to $13, in premarket trading.
New York Yankees and Duke Basketball
Recent IMTX News
- Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update • GlobeNewswire Inc. • 09/16/2024 09:25:00 AM
- Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 • GlobeNewswire Inc. • 09/06/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 11:07:01 AM
- Immatics Announces Second Quarter 2024 Financial Results and Business Update • GlobeNewswire Inc. • 08/13/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/31/2024 11:07:40 AM
- Immatics Appoints Alise Reicin to Board of Directors • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/22/2024 08:05:27 PM
- Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024 • GlobeNewswire Inc. • 07/18/2024 01:00:00 PM
- Immatics Announces First Quarter 2024 Financial Results and Business Update • GlobeNewswire Inc. • 05/14/2024 11:00:00 AM
- Immatics Announces Full Year 2023 Financial Results and Corporate Update • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/22/2024 05:52:26 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/19/2024 01:58:09 PM
- Immatics Announces Pricing of $175 Million Public Offering • GlobeNewswire Inc. • 01/18/2024 01:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/17/2024 09:11:11 PM
- Immatics Announces Proposed Public Offering • GlobeNewswire Inc. • 01/17/2024 09:01:00 PM
- DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing • PR Newswire (US) • 01/16/2024 09:06:00 AM
- DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing • PR Newswire (US) • 01/16/2024 08:59:00 AM
- Levicept Appoints Eliot Forster as CEO • GlobeNewswire Inc. • 11/30/2023 09:00:00 AM
- Immatics Announces Third Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 11/14/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/08/2023 12:30:38 PM
- Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial • GlobeNewswire Inc. • 11/08/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/24/2023 11:10:46 AM
- Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy • GlobeNewswire Inc. • 10/24/2023 11:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM